A patent review of arginine methyltransferase inhibitors (2010–2018)

References

• Paik WK, Kim S. Enzymatic methylation of protein fractions from calf thymus nuclei. Biochem Biophys Res Commun. 1967 Oct 11;29(1):14–20.
   PubMed Web of Science ®Google Scholar
• Cura V, Troffer-Charlier N, Lambert MA, et al. Cloning, expression, purification and preliminary X-ray crystallographic analysis of mouse protein arginine methyltransferase 7. Acta Crystallogr F Struct Biol Commun. 2014 Jan;70(Pt 1):80–86.
   PubMedGoogle Scholar
• Chumanov RS, Kuhn PA, Xu W, et al. Expression and purification of full-length mouse CARM1 from transiently transfected HEK293T cells using HaloTag technology. Protein Expr Purif. 2011 Apr;76(2):145–153.
   PubMed Web of Science ®Google Scholar
• Frankel A, Yadav N, Lee J, et al. The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. J Biol Chem. 2002 Feb 1;277(5):3537–3543.
   PubMed Web of Science ®Google Scholar
• Rho J, Choi S, Seong YR. PRMT5, which forms distinct homo-oligomers, is a member of the protein-arginine methyltransferase family. J Biol Chem. 2001 Apr 6;276(14):11393–11401.
   PubMed Web of Science ®Google Scholar
• Frankel A, Clarke S. PRMT3 is a distinct member of the protein arginine N-methyltransferase family. Conferral of substrate specificity by a zinc-finger domain. J Biol Chem. 2000 Oct 20;275(42):32974–32982.
   PubMed Web of Science ®Google Scholar
• Tang J, Gary JD, Clarke S, et al. PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. J Biol Chem. 1998 Jul 3;273(27):16935–16945.
   PubMed Web of Science ®Google Scholar
• Cook JR, Lee JH, Yang ZH, et al. FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues. Biochem Biophys Res Commun. 2006 Apr 7;342(2):472–481.
   PubMed Web of Science ®Google Scholar
• Lee J, Sayegh J, Daniel J, et al. PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem. 2005 Sep 23;280(38):32890–32896.
   PubMed Web of Science ®Google Scholar
• Lee JH, Cook JR, Yang ZH, et al. PRMT7, a new protein arginine methyltransferase that synthesizes symmetric dimethylarginine. J Biol Chem. 2005 Feb 4;280(5):3656–3664.
   PubMed Web of Science ®Google Scholar
• Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013 Jan;13(1):37–50.
   PubMed Web of Science ®Google Scholar
• Fulton MD, Brown T, Zheng YG. Mechanisms and inhibitors of histone arginine methylation. Chem Rec. 2018 Dec;18(12):1792–1807.
   PubMed Web of Science ®Google Scholar
• Gathiaka S, Boykin B, Caceres T, et al. Understanding protein arginine methyltransferase 1 (PRMT1) product specificity from molecular dynamics. Bioorg Med Chem. 2016 Oct 15;24(20):4949–4960.
   PubMed Web of Science ®Google Scholar
• Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell. 2005 Apr 29;18(3):263–272.
   PubMed Web of Science ®Google Scholar
• Trojer P, Dangl M, Bauer I, et al. Histone methyltransferases in Aspergillus nidulans: evidence for a novel enzyme with a unique substrate specificity. Biochemistry. 2004 Aug 24;43(33):10834–10843.
   PubMed Web of Science ®Google Scholar
• Pahlich S, Zakaryan RP, Gehring H. Protein arginine methylation: cellular functions and methods of analysis. Biochim Biophys Acta. 2006 Dec;1764(12):1890–1903.
   PubMed Web of Science ®Google Scholar
• Feng Y, Maity R, Whitelegge JP, et al. Mammalian protein arginine methyltransferase 7 (PRMT7) specifically targets RXR sites in lysine- and arginine-rich regions. J Biol Chem. 2013 Dec 27;288(52):37010–37025.
   PubMed Web of Science ®Google Scholar
• Gary JD, Lin WJ, Yang MC, et al. The predominant protein-arginine methyltransferase from Saccharomyces cerevisiae. J Biol Chem. 1996 May 24;271(21):12585–12594.
   PubMed Web of Science ®Google Scholar
• Katsanis N, Yaspo ML, Fisher EM. Identification and mapping of a novel human gene, HRMT1L1, homologous to the rat protein arginine N-methyltransferase 1 (PRMT1) gene. Mamm Genome. 1997 Jul;8(7):526–529.
   PubMed Web of Science ®Google Scholar
• Tang J, Frankel A, Cook RJ, et al. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem. 2000 Mar 17;275(11):7723–7730.
   PubMed Web of Science ®Google Scholar
• Huang R, Ding Q, Xiang Y, et al. Comparative analysis of DNA methyltransferase gene family in fungi: A focus on Basidiomycota. Front Plant Sci. 2016;7:1556.
   PubMedGoogle Scholar
• Horning BD, Suciu RM, Ghadiri DA, et al. Chemical proteomic profiling of human methyltransferases. J Am Chem Soc. 2016 Oct 12;138(40):13335–13343.
   PubMed Web of Science ®Google Scholar
• Katz JE, Dlakic M, Clarke S. Automated identification of putative methyltransferases from genomic open reading frames. Mol Cell Proteomics. 2003 Aug;2(8):525–540.
   PubMed Web of Science ®Google Scholar
• Cheng X, Roberts RJ. AdoMet-dependent methylation, DNA methyltransferases and base flipping. Nucleic Acids Res. 2001 Sep 15;29(18):3784–3795.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhou L, Cheng X. Crystal structure of the conserved core of protein arginine methyltransferase PRMT3. Embo J. 2000 Jul 17;19(14):3509–3519.
   PubMed Web of Science ®Google Scholar
• Bachand F. Protein arginine methyltransferases: from unicellular eukaryotes to humans. Eukaryot Cell. 2007 Jun; 6(6):889–898.
   PubMedGoogle Scholar
• Zhang X, Cheng X. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure. 2003 May;11(5):509–520.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Frazier M, Lu F, et al. Crystal structure of the plant epigenetic protein arginine methyltransferase 10. J Mol Biol. 2011 Nov 18;414(1):106–122.
   PubMed Web of Science ®Google Scholar
• Morales Y, Caceres T, May K, et al. Biochemistry and regulation of the protein arginine methyltransferases (PRMTs). Arch Biochem Biophys. 2016 Jan;15(590):138–152.
   Google Scholar
• Li KKC, Chau BL, Lee KAW. Differential interaction of PRMT1 with RGG-boxes of the FET family proteins EWS and TAF15. Protein Sci. 2018 Mar;27(3):633–642.
   PubMed Web of Science ®Google Scholar
• Wolf SS. The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans. Cell Mol Life Sci. 2009 Jul;66(13):2109–2121.
   PubMed Web of Science ®Google Scholar
• Nicholson TB, Chen T, Richard S. The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation. Pharmacol Res. 2009 Dec;60(6):466–474.
   PubMed Web of Science ®Google Scholar
• Blanc RS, Richard S. Arginine methylation: the coming of age. Mol Cell. 2017 Jan 5;65(1):8–24.
   PubMed Web of Science ®Google Scholar
• Lee DY, Teyssier C, Strahl BD, et al. Role of protein methylation in regulation of transcription. Endocr Rev. 2005 Apr;26(2):147–170.
   PubMed Web of Science ®Google Scholar
• An W, Kim J, Roeder RG. Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell. 2004 Jun 11;117(6):735–748.
   PubMed Web of Science ®Google Scholar
• Shilatifard A. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol. 2008 Jun;20(3):341–348.
   PubMed Web of Science ®Google Scholar
• Molina-Serrano D, Schiza V, Kirmizis A. Cross-talk among epigenetic modifications: lessons from histone arginine methylation. Biochem Soc Trans. 2013 Jun;41(3):751–759.
   PubMedGoogle Scholar
• Guo H, Wang R, Zheng W, et al. Profiling substrates of protein arginine N-methyltransferase 3 with S-adenosyl-L-methionine analogues. ACS Chem Biol. 2014 Feb 21;9(2):476–484.
   PubMed Web of Science ®Google Scholar
• Guo A, Gu H, Zhou J, et al. Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics. 2014 Jan;13(1):372–387.
   PubMed Web of Science ®Google Scholar
• Vadnais C, Chen R, Fraszczak J, et al. GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nat Commun. 2018 Apr 12;9(1):1418.
   PubMedGoogle Scholar
• Du W, Amarachintha S, Erden O, et al. The Fanconi anemia pathway controls oncogenic response in hematopoietic stem and progenitor cells by regulating PRMT5-mediated p53 arginine methylation. Oncotarget. 2016 Sep 13;7(37):60005–60020.
   PubMedGoogle Scholar
• Deng X, Lu T, Wang L, et al. Recruitment of the NineTeen Complex to the activated spliceosome requires AtPRMT5. Proc Natl Acad Sci U S A. 2016 May 10;113(19):5447–5452.
   PubMed Web of Science ®Google Scholar
• Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell. 2009 Jan 16; 33(1):1–13.
   PubMed Web of Science ®Google Scholar
• Lake AN, Bedford MT. Protein methylation and DNA repair. Mutat Res. 2007 May 1;618(1–2):91–101.
   PubMed Web of Science ®Google Scholar
• Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta. 2009 Jan;1789(1):45–57.
   PubMed Web of Science ®Google Scholar
• Baldwin RM, Morettin A, Cote J. Role of PRMTs in cancer: could minor isoforms be leaving a mark? World J Biol Chem. 2014 May 26;5(2):115–129.
   PubMedGoogle Scholar
• Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. Oncotarget. 2016 Oct 11;7(41):67532–67550.
   PubMedGoogle Scholar
• Hernandez SJ, Dolivo DM, Dominko T. PRMT8 demonstrates variant-specific expression in cancer cells and correlates with patient survival in breast, ovarian and gastric cancer. Oncol Lett. 2017 Mar;13(3):1983–1989.
   PubMed Web of Science ®Google Scholar
• Poisson LM, Munkarah A, Madi H, et al. A metabolomic approach to identifying platinum resistance in ovarian cancer. J Ovarian Res. 2015 Mar;26(8):13.
   Google Scholar
• Herrmann F, Pably P, Eckerich C, et al. Human protein arginine methyltransferases in vivo–distinct properties of eight canonical members of the PRMT family. J Cell Sci. 2009 Mar 1;122(Pt 5):667–677.
   PubMed Web of Science ®Google Scholar
• Le Romancer M, Treilleux I, Leconte N, et al. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell. 2008 Jul 25;31(2):212–221.
   PubMed Web of Science ®Google Scholar
• Deng X, Gu L, Liu C, et al. Arginine methylation mediated by the Arabidopsis homolog of PRMT5 is essential for proper pre-mRNA splicing. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19114–19119.
   PubMed Web of Science ®Google Scholar
• Bouras G, Deftereos S, Tousoulis D, et al. Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease? Curr Top Med Chem. 2013;13(2):180–200.
   PubMed Web of Science ®Google Scholar
• Rochette L, Lorin J, Zeller M, et al. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther. 2013 Dec;140(3):239–257.
   PubMed Web of Science ®Google Scholar
• Aletta JM, Hu JC. Protein arginine methylation in health and disease. Biotechnol Annu Rev. 2008;14:203–224.
   PubMedGoogle Scholar
• Dillon MB, Bachovchin DA, Brown SJ, et al. Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization. ACS Chem Biol. 2012 Jul 20;7(7):1198–1204.
   PubMed Web of Science ®Google Scholar
• Chan-Penebre E, Kuplast KG, Majer CR, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun;11(6):432–437.
   PubMed Web of Science ®Google Scholar
• Sack JS, Thieffine S, Bandiera T, et al. Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. Biochem J. 2011 Jun 1;436(2):331–339.
   PubMedGoogle Scholar
• van Haren M, van Ufford LQ, Moret EE, et al. Synthesis and evaluation of protein arginine N-methyltransferase inhibitors designed to simultaneously occupy both substrate binding sites. Org Biomol Chem. 2015 Jan 14; 13(2):549–560.
   PubMed Web of Science ®Google Scholar
• Ferreira de Freitas R, Ms E, Mm S, et al. Discovery of a potent class I protein arginine methyltransferase fragment inhibitor. J Med Chem. 2016 Feb 11;59(3):1176–1183.
   PubMed Web of Science ®Google Scholar
• Smil D, Eram MS, Li F, et al. Discovery of a dual PRMT5-PRMT7 inhibitor. ACS Med Chem Lett. 2015 Apr 9;6(4):408–412.
   PubMed Web of Science ®Google Scholar
• Cheng D, Yadav N, King RW, et al. Small molecule regulators of protein arginine methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892–23899.
   PubMed Web of Science ®Google Scholar
• Epizyme Inc. Arginine methyltransferase inhibitors and uses thereof. WO2014153214(A1). 2014.
   Google Scholar
• Epizyme Inc. Arginine methyltransferase inhibitors and uses thereof. WO2014153235(A2,A3). 2014.
   Google Scholar
• Epizyme Inc. Arginine methyltransferase inhibitors and uses thereof. WO2016044626A1. 2016.
   Google Scholar
• Glaxosmithkline IP Dev Ltd. Combination therapy. WO2018100532A1. 2018.
   Google Scholar
• Epizyme Inc. Prazole derivatives as arginine methyltransferase inhibitors and uses thereof. WO2014178954A1. 2014.
   Google Scholar
• Epizyme Inc. Arginine methyltransferase inhibitors and uses thereof. WO2016044585A1. 2016.
   Google Scholar
• Epizyme Inc. Pyrazole derivatives as PRMT1 inhibitors and uses thereof. WO 2014144659 A1. 2014.
   Google Scholar
• Epizyme Inc. Pyrazole derivatives as PRMT1 inhibitors and uses thereof. WO 2014153090 A1. 2014.
   Google Scholar
• Epizyme Inc. Pyrazole derivatives as PRMT1 inhibitors and uses thereof. WO 2014153172 A1. 2014.
   Google Scholar
• Epizyme Inc. Arginine methyltransferase inhibitors and uses thereof. WO 2014153208A1. 2014.
   Google Scholar
• Epizyme Inc. Arginine methyltransferase inhibitors and uses thereof. WO2014153226A1. 2014.
   Google Scholar
• Epizyme Inc. PRMT5 inhibitors and uses thereof. WO 2014100695A1. 2014.
   Google Scholar
• Epizyme Inc. PRMT5 inhibitors and uses thereof. WO 2014100716. 2014.
   Google Scholar
• Epizyme Inc. PRMT5 inhibitors and uses thereof. WO 2014100719A2. 2014.
   Google Scholar
• Epizyme Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof. WO 2014100730A1. 2014.
   Google Scholar
• Epizyme Inc. PRMT5 inhibitors and uses thereof. WO 2014100734. 2014.
   Google Scholar
• Epizyme Inc. PRMT5 inhibitors and uses thereof. WO 2015200677A2. 2015.
   Google Scholar
• Epizyme Inc. PRMT5 inhibitors and uses thereof. WO 2015200680A2. 2015.
   Google Scholar
• Epizyme Inc. PRMT5 inhibitors and uses thereof. WO 2016022605A1. 2016.
   Google Scholar
• Duncan KW, Rioux N, Boriack-Sjodin PA, et al. Structure and property guided design in the identification of PRMT5 tool compound EPZ015666. ACS Med Chem Lett. 2016 Feb 11;7(2):162–166.
   PubMed Web of Science ®Google Scholar
• Ctxt Pty Ltd. Tetrahydroisoquinolines as PRMT5-inhibitors. WO 2017153515A1. 2017.
   Google Scholar
• Ctxt Pty Ltd. 3-oxa-8-azabicyclo[3.2.1]octane derivatives and thier use in the treatment of cancer and hemoglobinopathies. WO 2017153519A1. 2017.
   Google Scholar
• Ctxt Pty Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors. WO 2016034675A1. 2016.
   Google Scholar
• Ctxt Pty Ltd. Tetrahydroisoquinolines as PRMT5 inhibitors. WO 2017153513A1. 2017.
   Google Scholar
• Ctxt Pty Ltd. PRMT5 inhibitors. WO 2017153518A1. 2017.
   Google Scholar
• Ctxt Pty Ltd. Pyridine derivatives and thier use in the treatment of cancer and hemoglobinopathies. WO2017153521A1. 2017.
   Google Scholar
• Prelude Therapeutics Inc. Selective inhibitors of protein arginine methyltransferase 5 PRMT5. WO2017218802A1. 2017.
   Google Scholar
• Prelude Therapeutics Inc. Selective inhibitors of protein arginine methyltransferase 5 (PRMT5). WO2018160824A1. 2018.
   Google Scholar
• Prelude Therapeutics Inc. Selective inhibitors of protein arginine methyltransferase 5 (PRMT5). WO2018152501A1. 2018.
   Google Scholar
• Prelude Therapeutics Inc. Selective inhibitors of protein arginine methyltransferase 5 (PRMT5). WO2018152548A1. 2018.
   Google Scholar
• Prelude Therapeutics Inc. Selective inhibitors of protein arginine methyltransferase 5 (PRMT5). WO2018160855A1. 2018.
   Google Scholar
• Cancer Therapeutics CRC Pty Ltd. 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase. WO 2014128465A1. 2014.
   Google Scholar
• Ohio State Innovation Foundation. Inhibitors of PRMT5 and methods of their use. WO2014145214A2. 2014.
   Google Scholar
• Janssen Pharmaceutica NV. Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as PRMT5 inhibitors. WO2018065365A1. 2018.
   Google Scholar
• Indiana Univ Research and Technology Corporation. Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment. WO2018081451A1. 2018.
   Google Scholar
• Shanghai Inst Materia Medica CAS. Compound having PRMT5 inhibitory activity, preparation for compound, and applications thereof. WO2018161922A1. 2018.
   Google Scholar
• Argonaut Therapeutics Ltd. Tricyclic compounds for use in treatment of proliferative disorders. WO2018167276A1. 2018.
   Google Scholar
• Hl R, Zurita-Lopez CI, Clarke S, et al. Mechanistic studies on transcriptional coactivator protein arginine methyltransferase 1. Biochemistry. 2011 Apr 26;50(16):3332–3345.
   PubMed Web of Science ®Google Scholar
• Sichuan University. Compounds inhibiting PRMT7 and their preparation and application. CN108503623A. 2018.
   Google Scholar
• Glaxosmithkline IP Dev Ltd. Combination therapy. WO2018100534A1. 2018.
   Google Scholar
• Glaxosmithkline IP Dev Ltd. Combination therapy. WO2018100535A1. 2018.
   Google Scholar
• Hu H, Qian K, Ho MC, et al. Small molecule inhibitors of protein arginine methyltransferases. Expert Opin Investig Drugs. 2016;25(3):335–358.
   PubMed Web of Science ®Google Scholar
• Univ Jinan. Composition for inhibiting growth of osteosarcoma by targeting PRMT5 (protein arginine methyltransferase 5) and preparation method thereof. CN105497034A. 2016.
   Google Scholar
• Univ Ohio State Res Found. Compositions and methods for cancer detection and treatment. WO2011079236A1. 2011.
   Google Scholar
• Glaxosmithkline IP Dev Ltd. Methods of treating cancer. WO2018100536A1. 2018.
   Google Scholar
• Broad Inst Inc. Selective treatment of PRMT5 dependent cancer. WO2016145150A2. 2016.
   Google Scholar
• Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008 Sep 11;27(40):5348–5353.
   PubMed Web of Science ®Google Scholar
• Novartis AG. Compositions and methods for diagnosis and treatment of prostate cancer. WO 2016089883A1. 2016.
   Google Scholar
• Univ Sichuan. Application of PRMT1 (protein arginine N-methyltransferase 1) inhibitor to preparation of drug for treating cocaine addiction. CN 105125571A. 2015.
   Google Scholar
• Blat Y. Non-competitive inhibition by active site binders. Chem Biol Drug Des. 2010 Jun;75(6):535–540.
   PubMed Web of Science ®Google Scholar
• Wang C, Jiang H, Jin J, et al. Development of potent type I Protein Arginine Methyltransferase (PRMT) inhibitors of leukemia cell proliferation. J Med Chem. 2017 Nov 9;60(21):8888–8905.
   PubMed Web of Science ®Google Scholar
• Ms E, Shen Y, Szewczyk M, et al. A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases. ACS Chem Biol. 2016 Mar 18;11(3):772–781.
   PubMed Web of Science ®Google Scholar
• Brehmer D, Wu T, Mannens G, et al. Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models. Cancer Res. 2017;77(13Supplement):DDT02-04-DDT02-04.
   Google Scholar
• Sv G, Kellner WA, Thompson C, et al. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Sci Rep. 2018 Jun 26;8(1):9711.
   PubMedGoogle Scholar